$XBI +$134.4 +0.59%
Covid Updates
$TLSA +6.3% Tiziana Responds to UK Call for Development of Innovative 'Take Home' Treatments for COVID-19 Disease. source
Pipeline Updates
$AMPE -0.6% Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK. source
$ACRX +2.9% Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials. source
$TPTX +3.8% Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer. source
$AGEN +6.4% Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer. source
$PHAS +0.8% PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab. source
$AMRX -3.6% Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab. source
$SYBX +5.6% Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease. source
$VKTX +5.3% Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214. source
$HZNP +1.4% Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics. source
$FGEN +1.7% FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease. source
$OPK +1.9% OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland. source
$APLT +3.3% Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia. source
$EGRX +3.2% Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin. source
$AERI +0.6% Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan. source
$IRWD 0% Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C). source
$PRTA -15.5% Participated in JMP Securities Life Sciences Conference on 6/16/21. source
$CLSD +13.8% On 6/15 Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD. source
$CAPR +15.0% Participating in BIO Digital 2021 June 14-18.
Financial Updates
$JAZZ -1.9% Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc. source
$NOVN -21.7% Novan Announces Pricing of $40 Million Public Offering of Common Stock. source
Posted by FS
Comments